Trial Profile
A retrospective cohort study of severe skin toxicities induced by a BRAF inhibitor-vemurafenib in patients with melanoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Nov 2016
Price :
$35
*
At a glance
- Drugs Vemurafenib (Primary) ; Dabrafenib
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 23 Nov 2016 New trial record